A Reappraisal of Women’s Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50–59 Years of Age

Table 2

Women 50–59 years of age at trial entry: WHI Estrogen-Alone Trial outcomes, 13-year cumulative long-term follow-up (intervention phase + postintervention phase).

Outcome	Hazard ratio (95% CI); Women 50–59 years of age CEE versus placebo	for interaction (trend by age) for all participants, 50–79 years
Coronary heart disease (primary trial endpoint)^a	0.65 (95% CI, 0.44–0.96)^†	0.12
Myocardial infarction	0.60 (95% CI, 0.39–0.91)^†	0.007^‡
Invasive breast cancer	0.76 (95% CI, 0.52–1.11)	0.70
All cancer types	0.80 (95% CI, 0.64–0.99)^†	0.18
All-cause death	0.78 (95% CI, 0.59–1.03)	0.10
Global index^b	0.82 (95% CI, 0.68–0.98)^†	0.01^‡

Coronary heart disease: nonfatal myocardial infarction or coronary death.
^bGlobal index represents the first event for each participant from among the following: coronary heart disease, stroke, pulmonary embolism, invasive breast cancer, colorectal cancer, hip fracture, or death due to other causes.
^†95% confidence interval does not include 1.0.
^‡Statistically significant (95% CI) for interaction (trend by age).
CEE: conjugated equine estrogens; CI: confidence interval; WHI: Women’s Health Initiative.
Source for outcomes: [3].